-
Kenya's economy faces climate change risks: World Bank
-
US Afghans in limbo after Washington soldier attack
-
Nasdaq rallies again while yen falls despite BOJ rate hike
-
US university killer's mystery motive sought after suicide
-
IMF approves $206 mn aid to Sri Lanka after Cyclone Ditwah
-
Rome to charge visitors for access to Trevi Fountain
-
Stocks advance with focus on central banks, tech
-
Norway crown princess likely to undergo lung transplant
-
France's budget hits snag in setback for embattled PM
-
Volatile Oracle shares a proxy for Wall Street's AI jitters
-
Japan hikes interest rates to 30-year-high
-
Brazil's top court strikes down law blocking Indigenous land claims
-
'We are ghosts': Britain's migrant night workers
-
Asian markets rise as US inflation eases, Micron soothes tech fears
-
Trump signs $900 bn defense policy bill into law
-
EU-Mercosur deal delayed as farmers stage Brussels show of force
-
Harrison Ford to get lifetime acting award
-
Trump health chief seeks to bar trans youth from gender-affirming care
-
Argentine unions in the street over Milei labor reforms
-
Brazil open to EU-Mercosur deal delay as farmers protest in Brussels
-
Brussels farmer protest turns ugly as EU-Mercosur deal teeters
-
US accuses S. Africa of harassing US officials working with Afrikaners
-
ECB holds rates as Lagarde stresses heightened uncertainty
-
Trump Media announces merger with fusion power company
-
Stocks rise as US inflation cools, tech stocks bounce
-
Zelensky presses EU to tap Russian assets at crunch summit
-
Danish 'ghetto' residents upbeat after EU court ruling
-
ECB holds rates but debate swirls over future
-
Bank of England cuts interest rate after UK inflation slides
-
Have Iran's authorities given up on the mandatory hijab?
-
British energy giant BP extends shakeup with new CEO pick
-
EU kicks off crunch summit on Russian asset plan for Ukraine
-
Sri Lanka plans $1.6 bn in cyclone recovery spending in 2026
-
Most Asian markets track Wall St lower as AI fears mount
-
Danish 'ghetto' tenants hope for EU discrimination win
-
What to know about the EU-Mercosur deal
-
Trump vows economic boom, blames Biden in address to nation
-
ECB set to hold rates but debate swirls over future
-
EU holds crunch summit on Russian asset plan for Ukraine
-
Nasdaq tumbles on renewed angst over AI building boom
-
Billionaire Trump nominee confirmed to lead NASA amid Moon race
-
CNN's future unclear as Trump applies pressure
-
German MPs approve 50 bn euros in military purchases
-
EU's Mercosur trade deal hits French, Italian roadblock
-
Warner Bros rejects Paramount bid, sticks with Netflix
-
Crude prices surge after Trump orders Venezuela oil blockade
-
Warner Bros. Discovery rejects Paramount bid
-
Doctors in England go on strike for 14th time
-
Ghana's Highlife finds its rhythm on UNESCO world stage
-
Stocks gain as traders bet on interest rate moves
Seventh person likely 'cured' of HIV, doctors announce
A 60-year-old German man is likely the seventh person to be effectively cured from HIV after receiving a stem cell transplant, doctors announced on Thursday.
The painful and risky procedure is for people who have both HIV and aggressive leukaemia, so is not an option for almost all of the nearly 40 million people living with the deadly virus across the world.
The German man, whose wished to remain anonymous, was dubbed the "next Berlin patient".
The original Berlin patient, Timothy Ray Brown, was the first person declared cured of HIV back in 2008. Brown died from cancer in 2020.
The second man from Berlin to achieve long-term HIV remission was announced ahead of the 25th International AIDS Conference being held in the German city of Munich next week.
He was first diagnosed with HIV in 2009, according to the research abstract being presented at the conference.
The man received a bone marrow transplant for his leukaemia in 2015. The procedure, which has a 10 percent risk of death, essentially replaces a person's immune system.
Then he stopped taking anti-retroviral drugs -- which reduce the amount of HIV in the blood -- in late 2018.
Nearly six years later, he appears to be both HIV and cancer free, the medical researchers said.
Christian Gaebler, a doctor-researcher at Berlin's Charite university hospital treating the patient, told AFP that the team cannot be "absolutely certain" every last trace of HIV has been eradicated.
But "the patient's case is highly suggestive of an HIV cure," Gaebler added. "He feels well and is enthusiastic about contributing to our research efforts."
- 'Promising' for wider cure -
International AIDS Society President Sharon Lewin said researchers hesitate to use the word "cure" because it is not clear how long they need to follow up such cases.
But more than five years in remission means the man "would be close" to being considered cured, she told a press conference.
There is an important difference between the man's case and the other HIV patients who have reached long-term remission, she said.
All but one of the other patients received stem cells from donors with a rare mutation in which part of their CCR5 gene was missing, blocking HIV from entering their body's cells.
Those donors had inherited two copies of the mutated CCR5 gene -- one from each parent -- making them "essentially immune" to HIV, Lewin said.
But the new Berlin patient is the first to have received stem cells from a donor who had inherited only one copy of the mutated gene.
Around 15 percent of people from European origin have one mutated copy, compared to one percent for both.
Researchers hope the latest success means there will be a much larger potential donor pool in the future.
The new case is also "promising" for the wider search for an HIV cure that works for all patients, Lewin said.
This is "because it suggests that you don't actually have to get rid of every single piece of CCR5 for gene therapy to work," she added.
The Geneva patient, whose case was announced at last year's AIDS conference, is the other exception among the seven. He received a transplant from a donor without any CCR5 mutations -- yet still achieved long-term remission.
This showed that the effectiveness of the procedure was not just down to the CCR5 gene, Lewin said.
X.Wong--CPN